Highlights
•
Olaparib monotherapy at clinical concentrations induces cell death in AML blasts.
•
AML blasts express undetectable BRCA1 protein.
•
PARP1 and γH2AX are biomarkers to identify the response of AML to olaparib.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
|
Krishan Maggon 's curator insight,
April 19, 2015 3:03 AM
Citation: Cesano A, Willman CL, Kopecky KJ, Gayko U, Putta S, et al. (2015) Cell Signaling-Based Classifier Predicts Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia. PLoS ONE 10(4): e0118485. doi:10.1371/journal.pone.0118485 |
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Volume 1852, Issue 3, March 2015, Pages 462–472
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparibIsabella Faraonia, b, , , Mirco Compagnoneb, , Serena Lavorgnab, c, , Daniela Francesca Angelinid, , Maria Teresa Cencionid, , Eleonora Pirasd, , Paola Panettab, c, , Tiziana Ottoneb, c, , Susanna Dolcic, , Adriano Vendittic, , Grazia Graziania, 1, , Francesco Lo-Cocob, c, 1, doi:10.1016/j.bbadis.2014.12.001